This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to Bactria Pharmaceuticals LLC is providing $274,937 to develop therapeutic drugs that restore antibiotic sensitivity in bacteria that cause severe healthcare-associated infections. The goal is to combat antimicrobial resistance in gram-negative pathogens through the use of small molecule efflux pump inhibitors (EPIs). The project involves three key activities: cryo-electron microscopy to understand...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $490,093 to the University of Maryland, College Park to develop a rapid antibiotic susceptibility testing platform. The platform will isolate bacteria directly from whole blood, identify pathogens, and evaluate their antibiotic response within 75 minutes, enabling clinicians to quickly determine appropriate targeted...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $984,381 to Cobio Diagnostics Inc. in Aurora, Colorado aims to expand a diagnostic tool that enables rapid, direct-from-specimen identification and antimicrobial susceptibility testing of major bloodborne bacterial pathogens. The project will develop a regulatory pathway for FDA clearance, characterize antibodies to expand the test, and validate the expanded tests...
This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $305,000 to Resonantia Diagnostics, Inc. to develop a rapid diagnostic platform for identifying pathogens and determining antimicrobial susceptibility within 60 minutes. The project aims to advance an acoustic sensor-based technology that can accurately detect pathogens at low concentrations and test their susceptibility to a diverse range of...
This $270,128 SBIR Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a low-cost, field-use DNA-based rapid diagnostic device for detecting plant diseases. The project aims to create a user-friendly, battery-operated testing kit that allows farmers to quickly identify diseases like citrus greening in their fields, enabling early intervention and more sustainable farming practices. The 9-month...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $295,561 to Biosensing Instrument Inc. to develop a commercial prototype of their Plasmonic Scattering Microscopy (PSM) technology. The PSM system aims to enable high-throughput, label-free quantification of membrane protein binding kinetics on single cells in their native cellular microenvironment. This represents a...
Cobio Diagnostics Inc. received a $256,000 Project Grant award from the National Science Foundation on April 1, 2021 to support work concluding on March 31, 2022. The grant was awarded under the NSF's Engineering program (CFDA 47.041), which aims to improve quality of life and economic strength through engineering research and education. Specifically, the grant funds Cobio Diagnostics' "SBIR PHASE I: PHAGE-AMPLIFIED IDENTIFICATION AND ANTIMICROBIAL SUSCEPTIBILITY TEST" project. This...
This $275,000 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program supports the development of a label-free, high-resolution, high-throughput protein screening platform called Vibrational Spectroscopy with Metasurface Optics (VISMO). The technology aims to enable simultaneous, minute-scale measurement of millions of protein samples, which would dramatically improve the lengthy and costly cycles...
This Project Grant award of $305,000 from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program will support the development of a novel mammalian cell-based nano-biological coating for implantable medical devices at Novaurum Biosciences Incorporated in Somerville, MA. The project aims to address the critical issue of implant-related infections, which cost the U.S. healthcare system over $8.6 billion annually, by creating a biocompatible and...
Biomesense Inc. received a $255,658 National Science Foundation SBIR Phase I Project Grant to develop a novel biosensor to accelerate investigations of COVID-19 and the gut microbiome. Funded under the NSF Engineering program (CFDA 47.041), this six-month award beginning January 15, 2021 supports the company's work to design a portable, low-cost biosensor device capable of rapidly detecting SARS-CoV-2 and analyzing gut microbiome composition directly from patient samples. The NSF Directorate for...